Formulation Development
Ocuphire Pharma Announces Full Phase 3 Results of Phentolamine Ophthalmic Solution for Pharmacologically Induced Mydriasis in Ophthalmology
Ocuphire Pharma, Inc. recently announced the publication of full results from two pivotal Phase 3 clinical trials (MIRA-2 and MIRA-3) that evaluated the safety and…
GRI Bio Granted Patent for Proprietary Natural Killer T Cell Modulators for Prevention & Treatment of Inflammatory Conditions
GRI Bio, Inc. recently announced it has received a Decision to Grant notice from the Japan Patent Office (JPO) for the patent application No. 2023-000750…
Dupixent Approved in the US as the First-Ever Biologic Medicine for Patients With COPD
The US FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic…
FDA Approves First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
Bristol Myers Squibb recently announced the US FDA has approved COBENFY (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults.…
Evaxion Significantly Expands Vaccine Development Collaboration With MSD
Evaxion Biotech A/S recently announced it has entered into an option and license agreement with MSD (tradename of Merck & Co., Inc.) for two preclinical…
Acumen Pharmaceuticals Extends Collaboration With Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
Acumen Pharmaceuticals, Inc. recently announced it has extended its collaboration with Lonza to enable the potential future commercial launch of sabirnetug (ACU193). Sabirnetug is the…
GRI Bio Receives Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621
GRI Bio, Inc. recently announced the authorization of its Clinical Trial Application (CTA) by the Australian Medicines and Healthcare products Regulatory Agency (MHRA) and the…
ImmunoPrecise Antibodies Advances Therapeutic Innovation With Groundbreaking Rabbit Antibody Developments
ImmunoPrecise Antibodies Ltd. (IPA) recently announced the clinical progress achieved with rabbit monoclonal antibodies designed and developed using IPA’s proprietary B Cell Select platform for…
Evonik Launches EUDRACAP Colon Functional Capsules for the Targeted Delivery of Oral Drugs
Evonik is expanding its EUDRACAP portfolio with a new functional, ready-to-fill capsule that enables the delivery of sensitive active ingredients to the ileo-colonic region. EUDRACAP…
Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program for the Treatment of Ulcerative Colitis
Palisade Bio, Inc. recently provided an update on its progress toward the launch of its Phase 1 human clinical study for PALI-2108 for the treatment of…
Sanner Group Acquires Gilero to Expand Global Medical Device Offering
Sanner Group has acquired Gilero LLC, a world class medical device design, development, and contract manufacturer headquartered in Durham, NC. The addition of Gilero will…
GoLiver Therapeutics Awarded Innovation in Biotherapies & Bioproduction Call for its GOCLINICALS Project Dedicated to Novel Stem Cell-Based Liver Therapy
GoLiver Therapeutics recently announced it has won the Innovations in Biotherapies and Bioproduction call for proposal launched by the French government to make France a…
PCI Pharma Services Invests Over $365 Million in EU, US Facilities for Clinical & Commercial Supply of Advanced Drug Delivery & Drug-Device Combination Products
PCI Pharma Services is investing more than $365 million in infrastructure supporting the clinical and commercial-scale final assembly and packaging of drug-device combination products utilizing advanced…
Lonza & Vertex Sign a Long-Term Commercial Supply Agreement for CASGEVY
Lonza, a global manufacturing partner to the pharmaceutical, biotech, and nutraceutical markets, recently announced the signature of a long-term commercial supply agreement for CASGEVY (exagamglogene…
Quell Therapeutics Expands Manufacturing Capabilities for CAR-Treg Cell Therapy Pipeline Through Partnership With eXmoor pharma
Quell Therapeutics Ltd and eXmoor pharma recently announced a strategic partnership for the manufacture of multiple autologous engineered CAR-Treg cell therapies in Quell’s pipeline targeting autoimmune…
KSQ Therapeutics Announces FDA Clearance of IND Application for a CRISPR/Cas9 Engineered Tumor-Infiltrating Lymphocyte Therapy
KSQ Therapeutics, Inc., in collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) and the Cell Therapy Manufacturing Center (CTMC), recently announced…
Araris Biotech AG Expands IP Portfolio With Acquisition of Innate Pharma’s Portfolio
Araris Biotech AG recently announced it has entered into an agreement with Innate Pharma. Under the agreement, Innate will assign its portfolio of patents related…
Barinthus Bio Initiates Phase 1 Clinical Trial of for the Treatment of Celiac Disease
Barinthus Biotherapeutics plc recently announced the initiation of its first-in-human Phase 1 trial of VTP-1000 in adults with celiac disease. The randomized, placebo-controlled clinical trial,…
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus
Lipella Pharmaceuticals Inc. recently announced an update on its ongoing multi-center Phase 2a clinical trial evaluating LP-310 for the treatment of Oral Lichen Planus (OLP).…
WEBINAR ON DEMAND: Advantages of Carbopol® Polymers in Oral Formulations
In this video, the Lubrizol team together with the IMCD US team takes you through formulation aspects of Carbopol® polymers as well as the results of a case study on an Acetaminophen oral suspension formulation.
